Ticker brief
REGN REGENERON PHARMACEUTICALS
Consumer, Non-cyclical · Biotechnology
last close
$805.02
1 day
-1.7%
14 days
+7.8%
mkt cap
$68.6B
signals 14d
28
authors 14d
15
crowd 14d
-0.1σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 38% mid · 65 pctile own 1y | IV/HV 1.25× |
| Skew — 25Δ RR 30d | -0.023 54 pctile own 1y | balanced vs own range |
| Net dealer OI (NDOI) | +0.39 normal | 5-session Δ +0.06 (as of 2026-07-16) |
| OI alarm | quiet | last alarm 2025-09-25 (z=3.1) |
Sentiment — last 14 days
daily mean sentiment, 2026-10-02 → 2026-10-16 · now +0.36 (−1 bearish … +1 bullish)
Who spoke15
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @OzmosiHealth | C | · | 9 | +0.09 |
| @harry03994688 | A | -0.16 | 3 | +0.53 |
| @alphaticaio | B | +1.81 | 2 | +0.33 |
| @BiopharmIQ | B | · | 2 | +0.13 |
| @MartyChargin | C | -0.56 | 2 | +0.50 |
| @USAnt_IDEA | C | -0.64 | 1 | +0.50 |
| @buzztickr | C | · | 1 | +0.00 |
| @VolumeLeaders | A | +0.57 | 1 | +0.00 |
| @financespotnews | C | +0.40 | 1 | -0.20 |
| @garcapital | C | -0.31 | 1 | +0.50 |
| @HedgeFundTips | B | +0.73 | 1 | +0.00 |
| @Couzin_Vinny | C | -1.03 | 1 | +0.25 |
| @AryaFintech | C | -1.41 | 1 | +0.25 |
| @StockTraderHub | C | -1.79 | 1 | +0.40 |
| @CHItrader | B | -0.22 | 1 | +0.50 |
Recent signals28of 28 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-10-16 | @BiopharmIQ | +0.10 | The post summarizes opening biotech moves and their company-specific catalysts. | +1.8% | tweet ↗ |
| 2026-10-16 | @OzmosiHealth | +0.35 | CHMP recommended EU approval of an updated Libtayo dosing regimen across approved cancer types. | +1.8% | tweet ↗ |
| 2026-10-16 | @MartyChargin | +0.50 | CHMP recommended approval of broader EU dosing options for Regeneron's Libtayo. | +1.8% | tweet ↗ |
| 2026-10-16 | @CHItrader | +0.50 | EMA's CHMP recommended approval of an alternative Libtayo dosing schedule across approved indications. | +1.8% | tweet ↗ |
| 2026-10-15 | @harry03994688 | +0.50 | Presents a bullish biotech basket thesis based on payer insulation, AI and improving clinical margins. | +1.1% | tweet ↗ |
| 2026-10-15 | @StockTraderHub | +0.40 | Lists five analyst upgrades, initiation and downgrade actions affecting the named stocks. | +1.1% | tweet ↗ |
| 2026-10-14 | @AryaFintech | +0.25 | Nasdaq heatmap identifies three winners and three losers in a mostly red session. | +3.4% | tweet ↗ |
| 2026-10-14 | @Couzin_Vinny | +0.25 | Expects a dealer-driven MRK squeeze after moving above the $145 call wall. | +3.4% | tweet ↗ |
| 2026-10-14 | @harry03994688 | +0.40 | Says cash-rich, staple and healthcare companies benefit from high rates. | +3.4% | tweet ↗ |
| 2026-10-13 | @HedgeFundTips | +0.00 | Shares a chart covering biotech earnings estimates and revisions. | +6.9% | tweet ↗ |
| 2026-10-13 | @OzmosiHealth | +0.00 | Reports presentation of Phase 3 garetosmab results. | +6.9% | tweet ↗ |
| 2026-10-12 | @MartyChargin | +0.50 | Reports favorable Phase 3 extension data and recent FDA approval for Pasatru in adult FOP. | +5.5% | tweet ↗ |
| 2026-10-12 | @OzmosiHealth | +0.50 | Pasatru produced zero new lesions during a trial extension. | +5.5% | tweet ↗ |
| 2026-10-12 | @garcapital | +0.50 | Regeneron's Phase 3 OPTIMA trial met its primary endpoint with a 90% reduction in new bone lesions. | +5.5% | tweet ↗ |
| 2026-10-09 | @financespotnews | -0.20 | Lists Thursday premarket losers and frames semiconductor weakness as an AI-trade reset. | +7.8% | tweet ↗ |
| 2026-10-08 | @VolumeLeaders | +0.00 | Reports IBB's largest trade since May 2020 and lists its principal holdings. | +8.8% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 cenvacibart results for 2026-10-26. | +8.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 amrecibart results for 2026-10-26. | +8.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 cenvacibart results for 2026-10-24. | +8.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 ubamatamab results for 2026-10-24. | +8.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 2 REGN-5668 ovarian-cancer results for 2026-10-26. | +8.5% | tweet ↗ |
| 2026-10-07 | @OzmosiHealth | +0.00 | Schedules Phase 1 fianlimab melanoma results for 2026-10-24. | +8.5% | tweet ↗ |
| 2026-10-07 | @alphaticaio | +0.50 | Reports REGN gained 2.5% after the author's earlier post. | +8.5% | tweet ↗ |
| 2026-10-06 | @buzztickr | +0.00 | Flags a registered Phase 3 readout scheduled for tomorrow. | +9.0% | tweet ↗ |
| 2026-10-06 | @BiopharmIQ | +0.15 | Biotech mover list quantifies positive opening reactions to coverage, clinical and regulatory updates. | +9.0% | tweet ↗ |
| 2026-10-04 | @USAnt_IDEA | +0.50 | Frames muscle preservation and visceral-fat reduction as the next obesity-drug battleground. | +9.5% | tweet ↗ |
| 2026-10-03 | @alphaticaio | +0.15 | Observes bullish wedge and flag patterns but explicitly says conviction is not yet sufficient for an alert. | +9.5% | tweet ↗ |
| 2026-10-02 | @harry03994688 | +0.70 | Advocates long-term investment in high-yield chipmakers and biotech firms with strong trial success. | +9.5% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.